10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the quarterly period ended March 31, 2015

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the transition period from ___________ to ___________

Commission File Number:  000-54626

SIGNAL ADVANCE, INC.

(Exact name of registrant as specified in its charter)

Texas

(State or Other Jurisdiction of Incorporation or Organization)

8731

(Primary Standard Industrial Classification Number)

76-0373052

(IRS Employer Identification Number)

2520 County Road 81

Rosharon, Texas 77583

(713) 510-7445

(Address and telephone number of principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:  None

Securities registered pursuant to Section 12(g) of the Act:  None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant as required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [X] No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Sec. 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes [X] No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.(Check one)

Large accelerated filer	[  ]	Accelerated filer	[  ]
Non-accelerated filer	[  ]	Smaller reporting company	[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes [  ] No [X]

The market value of the common equity held by non-affiliates: $5,286,480 based on a $1.00 closing price of the registrant's common stock as of the last business day of the registrant's year ended March 31, 2015.

As of May 13, 2015, the registrant had 10,330,077 shares of common stock, no par value, issued and outstanding.

Contents

PART I
ITEM 1.  Financial Statements and Supplementary Data	3
ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations	12
ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk	15
ITEM 4.  Controls and Procedures	16
PART II
ITEM 1.  Legal Proceedings	17
ITEM 1A.  Risk Factors	17
ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds	17
ITEM 3.  Defaults Upon Senior Securities	17
ITEM 4.  Mine Safety Disclosures	17
ITEM 5.  Other Information	17
ITEM 6.  Exhibits	18

2

PART I

ITEM 1.  Financial Statements and Supplementary Data

SIGNAL ADVANCE, INC.

FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION

Three Months Ended March 31, 2015

TABLE OF CONTENTS

FINANCIAL STATEMENTS (Unaudited)	Page No.
Balance Sheets	4
Statements of Operations	5
Statements of Cash Flows	6
Notes to Financial Statements	9-14

3

Signal Advance, Inc.

Balance Sheets

As of March 31, 2015 and December 31, 2014

(Unaudited)

	March 31, 2015			December 31, 2014
ASSETS
Current Assets
Cash or Cash Equivalent	$	4,125		$	37,177
Total Current Assets		4,125			37,177
Property and Equipment, net		4,665			4,730
Total Property and Equipment, net		4,665			4,730
Other Assets
Long-Term Investments		-			21,438
Total Other Assets		-			21,438
TOTAL ASSETS	$	8,790		$	63,345
LIABILITIES & SHAREHOLDERS' EQUITY (DEFICIT)
Liabilities
Line of Credit - Shareholder	$	25,945		$	10,769
Total Liabilities		25,945			10,769
Commitments
Shareholders' deficit
Common Stock - $0 par value
100,000,000 shares authorized
- shares issued and outstanding
10,305,077, as of March 31, 2015
10,273,410, as of December 31, 2014		-			-
Additional paid-in capital		5,177,835			5,130,335
Accumulated other comprehensive loss		(24,930	)		(24,930	)
Accumulated deficit		(5,170,060	)		(5,052,829	)
Total shareholders' equity (deficit)		(17,155	)		52,576
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY (DEFICIT)	$	8,790		$	63,345

See Accompanying Notes to the Financial Statements

4

Signal Advance, Inc.

Statements of Operations

Three Months Ended March 31, 2015 and 2014

(Unaudited)

	March 31, 2015			March 31, 2014
Revenue	$	-		$	-
Cost of revenue		-			-
Gross Profit		-			-
Expense
General & Administrative		8,568			8,642
Depreciation		368			415
Intellectual Property		2,690			7,418
Professional Services		71,417			16,686
Impairment expense		21,438			-
Research & Development		12,750			10,000
Total Expense		117,231			43,161
Net loss	$	(117,231	)	$	(43,161	)
Components of comprehensive loss:
Unrealized loss on available for sale securities		-			(13	)
Comprehensive loss		-			(13	)
Comprehensive loss	$	(117,231	)	$	(43,174	)
Loss per share - basic and diluted	$	(0.01	)	$	(0.00	)
Weighted average shares outstanding - basic and diluted		10,287,132			9,662,409

See Accompanying Notes to the Financial Statements

5

Signal Advance, Inc.

Statements of Cash Flow

Three Months Ended March 31, 2015 and 2014

(Unaudited)

	March 31, 2015			March 31, 2014
OPERATING ACTIVITIES
Net loss	$	(117,231	)	$	(43,161	)
Adjustments to reconcile Net Income
to net cash provided by operations:
Depreciation		368			415
Impairment of investment		21,438			-
Stock Compensation		47,500			100,000
Net cash provided by (used in) Operating Activities		(47,925	)		57,254
INVESTING ACTIVITIES
Purchase of property and equipment		(303	)		(660	)
Net cash used in Investing Activities		(303	)		(660	)
FINANCING ACTIVITIES
Capital Investment: Cash		-			42,000
Line of Credit - Shareholder, net		15,176			(81,599	)
Net cash provided by (used in) Financing Activities		15,176			(39,599	)
Net cash increase (decrease) for period		(33,052	)		16,995
Cash at beginning of period		37,177			11,497
Cash at end of period	$	4,125		$	28,492
Supplemental Disclosure
Interest paid	$	633		$	898
Non-Cash Transactions:
Unrealized loss on available for sale securities	$	-		$	13
Repayment of line of credit – shareholder in common stock	$	-		$	100,000

See Accompanying Notes to the Financial Statements

6

Signal Advance, Inc.

Notes to Financial Statements

March 31, 2015

(Unaudited)

NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION: The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 2015, are not necessarily indicative of the results that may be expected for the year ended December 31, 2015.

The Company's 10-K for the year ended December 31, 2014 should be read in conjunction with this report.

RECLASSIFICATIONS: For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the financial statement presentation used in 2015.

NATURE OF OPERATIONS AND ORGANIZATION:  Signal Advance, Inc. (the Company) was incorporated in Texas on June 4, 1992, is an engineering product and procedure development and consulting firm focused on the development of applications for emerging technologies. The Company has significant experience in computer technology, distributed information systems, and data acquisition and analysis systems, as well as, medical education, intellectual property protection and medical-legal litigation support. The Company has focused its resources on the improvement of signal detection systems through the development and refinement of its proprietary "Signal Advance" technology which has potential application in a wide range of medical applications, as well as applications outside of biomedicine.

CASH AND CASH EQUIVALENTS: The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

INTANGIBLE ASSETS OR LONG LIVED ASSETS: The Company anticipates amortizing intangible assets over their estimated useful lives unless such lives are deemed indefinite. Amortized intangible assets are tested for impairment based on undiscounted cash flows, and, if impaired, written down to fair value based on either discounted cash flows or appraised values. Intangible assets with indefinite lives are tested annually for impairment and written down to fair value as required. No impairment of intangible assets has been identified during any of the periods presented.

USE OF ESTIMATES IN FINANCIAL STATEMENT PREPARATION: The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company's financial statements include amounts and all adjustments that, in the opinion of management and based on management's best estimates and judgments, are necessary to make the financial statement not misleading. Actual results could differ from those estimates.

7

AVAILABLE FOR SALE SECURITIES: The Company holds certain investments that are treated as available-for-sale securities (FASB ASC 320-10-25) and stated at their fair market values. All investments are available for current operations and are classified as other assets in the balance sheet. Unrealized holding gains and losses are included as a component of other comprehensive income (loss) until realized (FASB ASC 320-35-1). Realized gains and losses are included in 'Other Income (Loss)' in the income statement.

INVESTMENTS IN A LIMITED LIABILITY COMPANY: The Company holds a minor investment (3%) in a Limited Liability Company (LLC). The equity method of accounting for investments in general partnerships is generally appropriate for accounting by limited partners for their investments in limited partnerships. The Company's interest is so minor as a limited partner that the Company has virtually no influence over the operating and financial policies of the LLC. As such, accounting for the investment using the cost method is appropriate. Under the cost method, income recognized by the investor is limited to distributions received, except that distributions that exceed the investor's share of earnings after the date of the investment are applied to reduce the carrying value of the investment.

Adjustments are made for impairment annually based on an impairment analysis per ASC 350-20-65-1 where the Company compares whether the fair value of the investment is less than its carrying amount which would result in impairment. The Company has recognized impairment as the LLC is dormant, currently having no commercial activity and no such activity is anticipated in the foreseeable future. As such, an adjustment for impairment was made during the three month period ended March 31, 2015 for the entire carrying value $21,438.

RESEARCH AND DEVELOPMENT: Research and development costs are expensed as incurred until technological feasibility can be determined (FASB ASC 730-10-25). Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval, marketability, licensing, lease, or sale when the net present value and useful life is able to be determined. Payments made to third parties subsequent to the aforementioned events will be capitalized. Amounts capitalized for such payments will be included in other intangibles, less the net of the accumulated amortization, once their useful lives can be determined.

REVENUE RECOGNITION: The Company revenues are generated by: 1) Providing consulting services; 2) Licensing intellectual property; and 3) Providing consulting services to licensees to facilitate implementation.

Revenue is not recognized until it is realized or realizable and earned (FASB Concepts Statement No. 5, Recognition and Measurement in Financial Statements of Business Enterprises, paragraphs 83-84). In accordance with ASC 605, 'Revenue Recognition,' the company recognizes as revenue the fees charged clients as referenced below because 1) persuasive evidence of an arrangement exists, 2) the fees charged as royalties and/or for services are substantially fixed or determinable during the period in which services are provided or royalties are collected, 3) the company and its clients understand the specific nature and terms of the agreed upon transactions, and 4) collectability is reasonable assured after services have been rendered, or according to a royalty payment schedule.

Consulting Revenue - For revenues generated by providing engineering, scientific and medical/legal consulting services. Services are charged at an hourly rate and clients are charged and revenue is recognized monthly.

8

License Revenue - As part of the Company's business model and as a result of the company's on-going investment in research and development, the company plans to license and sell the rights to certain of its intellectual property (IP) including internally developed patents, trade secrets and technological know-how. The typical license will call for a non-refundable initiation fee, escalating minimum royalties to be paid before a given product is marketed, and continuing royalties based on gross sales once marketing has begun, confirmed by annual audits. The license will also include a set amount of time for consulting. Licensees will also be required to participate in patent maintenance and defense.

Certain transfers of IP to third parties may be licensing/royalty-based, transaction-based, or other forms of transfer. Licensing/royalty-based fees involve transfers in which the company earns the income over time, as a lump-sum payment or the amount of income is not fixed or determinable until the licensee sells future related products (i.e., variable royalty, based upon licensee's revenue). Accordingly, following delivery and or legal conveyance of rights to the aforementioned IP to the client, and following inception of the license term, revenue is recognized in a manner consistent with the nature of the transaction and the earnings process.

Combined License/Consulting Revenue - in certain circumstances the license agreement will also include consulting services to facilitate the use of the Company's IP, in which case the arrangement may include multiple deliverables. If the client is dependent on the consulting services of the Company to bring value to the license then the license and consulting services will be considered a single unit of accounting. If, however, the license has value to the client, independent of the consulting services provided by the Company, then each deliverable has value on a standalone basis. As such each delivered item or items shall be considered a separate unit of accounting (FASB ASC 605-25).

Alternatively, license terms may contain a citation of milestones of achievement by the licensee. Each milestone may be tied to an increase in the minimum royalty. For example, biomedical milestones may include completion of animal trials, submission and then approval of 510K applications or pre-market approval by the FDA. Each licensee pursuing a biomedical application will be expected to develop its own clinical data to secure such pre-market notification (510k) or approval. Under these circumstances, the deliverable, or unit of accounting, consideration may be contingent on the substantive achievement of one or more milestones. As such, revenue is recognized in its entirety in the period in which the milestone is achieved (FASB ASC 605-28).

During the three month period ended March 31, 2015 and 2014, the Company recognized no revenue.

PROPERTY AND EQUIPMENT:  Fixed Assets (land, buildings and equipment) are carried at cost less accumulated depreciation. Depreciation is based on the estimated service lives of depreciable assets and is provided using the straight line method. In the case of disposals, assets and related depreciation are removed from the accounts, and the net amounts, less proceeds from disposal, are included in income.

INCOME TAXES:  The Company takes an asset and liability approach to financial accounting and reporting for income taxes. The difference between the financial statement and tax basis of assets and liabilities is determined annually.  Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the periods in which they are expected to affect taxable income. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will assure full realization (FASB ASC 740). As of March 31, 2015, the Company recorded a valuation allowance that reduced its deferred tax assets to zero.

9

CONCENTRATIONS OF CREDIT RISK: Financial instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of investment securities. Investment securities are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities can occur in the near term and that each change could materially affect the amounts reported in the financial statement.

GOING CONCERN: The Company is currently conducting operations. However, it has not yet generated sufficient operating revenue to fund its development activities to date. As such, the Company has relied on funding by the Company's President and the sale of its common stock. There is a substantial doubt that the Company will generate sufficient revenues in future years to meet its operating cash requirements. Accordingly, the Company's ability to continue operations in the short-term depends on its success in obtaining equity or debt financing in an amount sufficient to support its operations. This could raise doubt as to its ability to continue as a going concern. The financial statements do not include any adjustments that might result from this uncertainty.

NOTE B - INTELLECTUAL PROPERTY

Intellectual property protection is being pursued for the specifically identifiable intellectual property (IP) termed Signal Advance technology. The following table lists the patent applications and issued patents and their respective status:

Patent Office	Patent or Appl. No.	Status
United States	8452544	Issued May 2013
China	ZL 200880015288.2	Issued Nov. 2012
Europe	EP 08 75 4879.8	Under examination
Mexico	325278	Issued Apr. 2014
India	3465/KOLNP/2009	Not yet examined

Additional patent submissions related to specific applications, SA circuit configurations, and signal processing techniques are in preparation.

The IP derives from an assignment of the IP in the form of a patent application filed with the USPTO as well as any patents which issue as a result of U.S. and related international patent applications.

As ASSIGNEE, the Company is responsible for:

1) funding and executing activities required for any regulatory approval, development, implementation and commercialization;

2) introducing assigned products which incorporate the patent pending or patented technology to the commercial market;

3) make its best efforts to:

        a) develop and market assigned products and services, and

        b) increase and extend the commercialization of assigned products, and

4) commence the advertising and marketing assigned products not later than 24 months following the granting of the patent

10

The assignment was privately negotiated between the Company's President, Dr. Hymel (Assignor) and the remaining members of the board of directors for the Company (Assignee). Consideration to acquire the IP rights, in the form of equity (specifically 1,525,000 shares of SAI common stock, to date) was expensed as the assignment is considered a transaction between entities under common control (FASB ASC 805-50-30-5,6). The value of the common stock issued in exchange for the equity was based on the most recent private sales of stock (FASB ASC 505-50-30-6).  In addition, royalties are payable to Assignor on net sales and/or license fees as follows: a) <$10M: 6%; b) $10-$25M: 8%, and c)>$25M: 10%. Assignor's remedy for non-payment is the termination of the assignment.

The costs incurred in acquiring intellectual property assignments as well as the pursuit of domestic and international patent and trademark protection are expensed (included as "Intellectual Property" under expenses on the Statements of Operations. These costs include expenses to prepare and prosecute patent applications and protect the IP, include filing and issuance fees, fees for consultants, experts, advisors, patent attorneys, including foreign associates, patent applications, claims and other amendments, responses to office actions, etc. Any patent infringement case may hinder the Company's ability to generate revenues.

NOTE C - AVAILABLE FOR SALE SECURITIES

Approximate cost and fair value of available for sale securities (acquired January 10, 2011) as of March 31, 2015 and December 31, 2014 are as follows:

		Cost Gross		Gain(Loss)			Fair Value
Equity Securities Available for Sale	March 31, 2015	$	25,000	$	(25,000	)		-
Equity Securities Available for Sale	December 31, 2014	$	25,000	$	(25,000	)		-

NOTE D - PROPERTY AND EQUIPMENT

Property and equipment as of March 31, 2015 and December 31, 2014 are summarized as follows:

	March 31, 2015			December 31, 2014
Cost / Basis	$	128,778		$	128,475
Accumulated depreciation		(124,113	)		(123,745	)
Total property and equipment, net	$	4,665		$	4,730

Depreciation expense during the three months ended March 31, 2015 and 2014 were $368 and $415, respectively.

Note E – LINE OF CREDIT - SHAREHOLDER

The President has loaned funds to the Company under the terms of a Line of Credit Promissory Note negotiated with, and approved by, the Board of Directors. The line of credit is due on demand, unsecured, and bears interest at 2.5% per quarter.

As of March 31, 2015, the remaining balance payable was $25,945 including accrued interest of $633.

NOTE F - FACILITIES LEASE

The Company currently leases office space, from its president, on a month to month basis at a rate of $700 per month. Rental expense amounted to $2,100 for the three months ended March 31, 2015 and 2014.

NOTE G – EQUITY

During the three months ended March 31, 2015, the Company made the following Common Stock issuances:

1) 21,667 shares of common stock valued at $32,500 to consultants in exchange for services.

2) 10,000 shares of common stock valued at $15,000 to three members of the Board of Directors in exchange for services.

Subsequent to March 31, 2015, the Company issued 25,000 shares of common stock valued at $25,000 to consultants in exchange for services.

11

ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this quarterly report. This report may contain forward-looking statements which relate to future events or our future financial performance. These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "plan," "approximate" or "continue," or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events. Unless the context requires otherwise, the terms 'Company,' 'SAI,' 'SA,' 'we,' 'our,' and 'us' refer to Signal Advance Inc., a Texas corporation formed on June 4, 1992. Our unaudited financial statements are stated in United States Dollars and are prepared in accordance with U.S. Generally Accepted Accounting Principles.

RESULTS OF OPERATIONS

We have incurred recurring losses to date. Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

Our auditors have issued a going concern opinion as the Company has generated insufficient revenues to fund planned R&D, marketing and intellectual protection in the near-term. SAI will continue to rely on capital investment to cover the projected costs to execute the Company's business plan and commercialize its proprietary signal advance technology. We expect we will require additional capital to meet our long term operating requirements. We anticipate raising additional capital through, among other things, the sale of equity or debt securities. There is no assurance that the Company will be able to raise the required capital which would result in operations being scaled back accordingly.

The majority of the Company's resources are devoted to technology development and protection of its proprietary technology aa well as raising the required capital to execute our business plan.

INCOME:  In the three month periods ended March 31, 2015 and 2014, the Company recognized no revenue.

EXPENSES:  Expenses are classified into the following broad categories: Depreciation, impairment, Intellectual Property, Professional Services, Research & Development, Sales & Marketing and General & Administrative. SAI has engaged consultants to accomplish its goals over the last two years. Given sufficient capital, the majority of these consultants have expressed interest in working for us full-time. Professional Services includes expenses for accounting, legal, transfer agent and director's fees.

12

Expenses for the three month period ended March 31, 2015 and 2014, were as follows:

	March 31, 2015		March 31, 2014
General & Administrative	$	8,568	$	8,642
Intellectual Property		2,690		7,418
Professional Services		71,417		16,686
Research & Development		12,750		10,000
Impairment expense		21,438		-
Depreciation		368		415
Total Expense	$	117,231	$	43,161

The increase in expenses during the three month period ended March 31, 2015 for Professional Services reflects expenses related to the 1) seeking capital to fund on-going efforts related to in scientific, technical and commercial validation, business development and investigation into specific applications for our proprietary technology, and, 2) fulfillment of independent audit and reporting requirements of the Securities and Exchange Commission.  Impairment expense related to impairment of investment in LLC.

LIQUIDITY AND CAPITAL ASSETS

CURRENT ASSETS:  As of March 31, 2015 and December 31, 2014, the Company had cash and cash equivalents of $4,125 and $37,177, respectively. These assets are used as working capital to execute the Company's business plan. The Company requires additional capital through debt or equity financing to fund operations.

PROPERTY AND EQUIPMENT, NET: Property and Equipment, net as of March 31, 2015 and December 31, 2014 were $4,665 and $4,730, respectively.

OTHER ASSETS:  During the three month period ended March 31, 2015, it was determined that a long-term investment in an LLC was impaired for the entire carrying value. The change in fair value for the long-term investment resulted in an impairment loss of $21,438 during the three month period ended March 31, 2015.

LIABILITIES:  Liabilities include a line of credit from its President which was $10,769 on December 31, 2014 and rose to $25,945 by March 31, 2015.

SHAREHOLDERS' DEFICIT:  Accumulated deficit totaled $5,170,060 on March 31, 2015, up from $5,052,829 on December 31, 2014. The shares issued and outstanding as of March 31, 2015 and December 31, 2014 were 10,305,077 and 10,273,410, respectively.

OFF-BALANCE SHEET TRANSACTIONS:  There are no off-balance sheet items, all transactions are in U.S. dollars, and SAI is not currently subject to currency fluctuations or similar market risks.

SIGNIFICANT ACCOUNTING POLICIES

CASH AND CASH EQUIVALENTS:  The Company considers highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

13

AVAILABLE FOR SALE SECURITIES:  The Company holds certain investments that are treated as available-for-sale securities and stated at their fair market values. All investments are available for current operations and are classified as other assets in the balance sheet. Realized gains and losses are determined by the specific identification method and are included in 'Other Income (Loss)' in the income statement. There are currently no such available for sale securities.

INVESTMENTS IN A LIMITED LIABILITY COMPANY: The Company holds a minor (3%) investment in a Limited Liability Company (LLC). The equity method of accounting for investments in general partnerships is generally appropriate for accounting by limited partners for their investments in limited partnerships. The Company's interest is so minor as a limited partner that the Company has virtually no influence over the operating and financial policies of the LLC. As such, accounting for the investment using the cost method is appropriate.  Under the cost method, income recognized by the investor is limited to distributions received, except that distributions that exceed the investor's share of earnings after the date of the investment are applied to reduce the carrying value of the investment.

The long-term investment was impaired for the full carrying value of $21,438 during the three month period ended March 31, 2015 as the LLC is currently dormant.

RESEARCH AND DEVELOPMENT: Research and development expenses are expensed as incurred until technological feasibility can be determined. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval, marketability, licensing, lease, or sale when the net present value and useful life is able to be determined. Costs associated with intellectual property protection have been expensed until such time as the useful can be determined, at which time, amounts capitalized will be included in intangible property, less the net of accumulated amortization.

REVENUE RECOGNITION:  Revenue is not be recognized until it is realized or realizable and earned. An extended discussion regarding the sources of revenue expected as well as how revenue from these sources will be recognized can be found under 'Revenue Recognition' in the Financial Statements.

PROPERTY AND EQUIPMENT: Property and equipment are carried at cost less accumulated depreciation. Depreciation is based on the estimated service lives of depreciable assets and is provided using the straight line method. In the case of disposals, assets and related depreciation are removed from the accounts, and the net amounts, less proceeds from disposal, are included in income.

INCOME TAXES:  The Company takes an asset and liability approach to financial accounting and reporting for income taxes. Difference between the financial statement and tax basis of assets and liabilities is determined annually. Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the periods in which they are expected to affect taxable income. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will assure full realization. As of March 31, 2015, the Company recorded a valuation allowance that reduced its deferred tax assets to zero.

CONCENTRATIONS OF CREDIT RISK:  Financial instruments which may subject the Company to significant concentrations of credit risk consist primarily of investment securities. Investment securities are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities can occur in the near term and that such change could materially affect the amounts reported in the financial statements.

14

INTANGIBLE ASSETS OR LONG-LIVED ASSETS:  The Company amortizes intangible assets over their estimated useful lives unless such lives are deemed indefinite. Amortized intangible assets are tested for impairment based on undiscounted cash flows, and, if impaired, written down to fair value based on either discounted cash flows or appraised values. Intangible assets with indefinite lives are tested annually for impairment and written down to fair value as required.

DEFERRED TAX ASSET:  A valuation allowance was recognized for the full amount of the deferred tax asset because, based on the weight of available evidence, it is more likely than not that some portion or the entire deferred tax asset will not be realized.

NET LOSS PER SHARE: Basic loss per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding for the period.

PLAN OF OPERATION AND FUNDING

We anticipate that required working capital will continue to be funded through a combination of our existing funds and further issuances of securities. Working capital requirements will likely to increase in line with the business growth. Existing working capital, further advances, debt instruments, and firm commitments are expected to be adequate to fund our operations over the next three months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: i) technology development, ii) marketing and commercialization, and iii) intellectual property protection. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements.

Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Also, such securities may have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

MATERIAL COMMITMENTS: The Company currently leases office space, from its president, on a month to month basis at a rate of $700 per month.

PURCHASE OF SIGNIFICANT EQUIPMENT: We do not intend to purchase any significant equipment during the next six months.

ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk

Not applicable to smaller reporting companies.

15

ITEM 4.  Controls and Procedures

MANAGEMENT'S REPORT ON DISCLOSURE CONTROLS AND PROCEDURES:  Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that compliance with the policies or procedures may deteriorate.

Management evaluated the effectiveness of the Company's internal control over financial reporting as of March 31, 2015, using the criteria established in 'Internal Control-Integrated Framework' issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of March 31, 2015, based on the above referenced guidelines, the Company determined that there were control deficiencies that constituted material weaknesses, as described below.

1) We do not have an Audit Committee - While not being legally obligated to have an audit committee, it is the management's view that such a committee, including a financial expert member, is an important entity level control over the Company's financial statement. Currently the Board of Directors acts in the capacity of the Audit Committee, and does not include a member that is considered to be independent of management to provide the necessary oversight over management's activities.

2) We did not maintain appropriate cash controls - As of March 31, 2015, the Company has not maintained sufficient internal controls over financial reporting for the cash process, including failure to segregate cash handling and accounting functions, and did not require dual signature on the Company's bank accounts. Alternatively, the effects of poor cash controls were mitigated by the fact that the Company had limited transactions in their bank accounts.

3) We did not implement appropriate information technology controls - As of March 31, 2015, the Company retains copies of all financial data and material agreements and periodically make backups of the Company's data; however there is no formal procedure or evidence of normal backup of the Company's data or off-site storage of data in the event of theft, misplacement, or loss due to   unmitigated factors.

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company's internal controls.  As a result of the material weaknesses described above, management has concluded that the Company did not maintain effective internal control over financial reporting as of March 31, 2015 based on criteria established in Internal Control - Integrated Framework issued by COSO.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING:  There has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the effectiveness of our internal control over financial reporting as of March 31, 2015, that occurred subsequent to the evaluation that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

This quarterly report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to rules of the SEC applicable to an Emerging Growth Company  that permit the Company to provide only management's report in this quarterly report.

16

PART II

ITEM 1.  Legal Proceedings

We know of no legal proceedings to which we are a party or to which any of our property is the subject which are pending, threatened or contemplated or any unsatisfied judgments against us.

ITEM 1A.  Risk Factors

Not applicable to smaller reporting companies.

ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended March 31, 2015, the Company made the following Common Stock issuances:

1) 21,667 shares of common stock valued at $32,500 to two consultants in exchange for services.

2) 10,000 shares of common stock valued at $15,000 to three members of the Board of Directors in exchange for services.

Subsequent to March 31, 2015 the Company issued 25,000 shares of common stock valued at $25,000 to consultants in exchange for services.

These issuances of unregistered were exempt pursuant to Section 4(2) of the Securities Act as these were privately negotiated transactions in which there was no advertising and no commissions paid. Accordingly, the stock certificates representing these shares were issued with restrictive legends indicating that the shares have not been registered and may not be traded until registered or otherwise exempt from registration.

ITEM 3.  Defaults Upon Senior Securities

Not Applicable

ITEM 4.  Mine Safety Disclosures

Not Applicable

ITEM 5.  Other Information

Not Applicable

17

ITEM 6.  Exhibits

The following exhibits are filed as part of this Quarterly Report.

31.1:	Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act
31.2:	Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act
32.1:	Certification of Chief Executive Officer and Chief Financial Officer under Section 1350 as Adopted Pursuant Section 906 of the Sarbanes- Oxley Act
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

* Furnished herewith. XBRL (Extensible Business Reporting Language) information   is furnished and not filed or a part of a registration statement or prospectus   for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not   filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

18

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated:  May 15, 2015	SIGNAL ADVANCE, INC.
	By:  /s/ Chris M. Hymel
	Chris M. Hymel, President/Treasurer

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and as of the dates indicated.

SIGNATURE	TITLE	DATE
/s/ Chris M. Hymel	Member: Board of Directors, President	May 15, 2015
Chris M. Hymel	and Treasurer (Principal Executive, Financial  and Accounting Officer)
/s/ Malcolm Skolnick	Member: Board of Directors, Secretary	May 15, 2015
Malcolm H. Skolnick
/s/ Richard C. Seltzer	Member: Board of Directors	May 15, 2015
Richard C. Seltzer

19

EX-31

Exhibit 31.1:  Certification of Chief Executive Officer pursuant to Section
               302(a) of the Sarbanes-Oxley Act

                   CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
               PURSUANT TO SECTION 302(a) OF THE SARBANES OAXLEY-ACT


I, Chris M. Hymel, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Signal Advance, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a
   material fact or omit to state a material fact necessary to make the
   statements made, in light of the circumstances under which such statements
   were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
   information included in this report, fairly present in all material respects
   the financial condition, results of operations and cash flows of the
   registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and
   procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
   internal control over financial reporting (as defined in Exchange Act Rules
   13a-15(f) and 15d-15(f)) for the registrant and have:

   a. Designed such disclosure controls and procedures, or caused such
      disclosure controls and procedures, to be designed under my supervision,
      to ensure that material information relating to the registrant, including
      any consolidated subsidiaries, is made known to me by others within those
      entities, particularly during the period in which this report is being
      prepared;

   b. Designed such internal control over financial reporting, or caused such
      internal control over financial reporting to be designed under my
      supervision, to provide reasonable assurance regarding the reliability of
      financial reporting and the preparation of financial statements for
      external purposes in accordance with generally accepted accounting
      principles;

   c. Evaluated the effectiveness of the registrant's disclosure controls and
      procedures and presented in this report my conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end of
      the period covered by this report based on such evaluation; and

   d. Disclosed in this report any change in the registrant's internal control
      over financial reporting that occurred during the registrant's most recent
      fiscal quarter (the registrant's fourth fiscal quarter in the case of an
      annual report) that has materially affected, or is reasonably likely to
      materially affect, the registrant's internal control over financial
      reporting; and






                                        1

5. I have disclosed, based on my most recent evaluation of internal control over
   financial reporting, to the registrant's auditors and the audit committee of
   the registrant's board of directors (or persons performing the equivalent
   functions):

   a. All significant deficiencies and material weaknesses in the design or
      operation of internal control over financial reporting which are
      reasonably likely to adversely affect the registrant's ability to record,
      process, summarize and report financial information; and

   b. Any fraud, whether or not material, that involves management or other
      employees who have a significant role in the registrant's internal control
      over financial reporting.


     /s/Chris M. Hymel

     Chris M. Hymel
     President/Treasurer


May 13, 2015




































                                        2

EX-31

Exhibit 31.2:  Certification of Chief Financial Officer pursuant to Section
               302(a) of the Sarbanes-Oxley Act

                   CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
               PURSUANT TO SECTION 302(a) OF THE SARBANES OAXLEY-ACT


I, Chris M. Hymel, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Signal Advance, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a
   material fact or omit to state a material fact necessary to make the
   statements made, in light of the circumstances under which such statements
   were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
   information included in this report, fairly present in all material respects
   the financial condition, results of operations and cash flows of the
   registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and
   procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
   internal control over financial reporting (as defined in Exchange Act Rules
   13a-15(f) and 15d-15(f)) for the registrant and have:

   a. Designed such disclosure controls and procedures, or caused such
      disclosure controls and procedures, to be designed under my supervision,
      to ensure that material information relating to the registrant, including
      any consolidated subsidiaries, is made known to me by others within those
      entities, particularly during the period in which this report is being
      prepared;

   b. Designed such internal control over financial reporting, or caused such
      internal control over financial reporting to be designed under my
      supervision, to provide reasonable assurance regarding the reliability of
      financial reporting and the preparation of financial statements for
      external purposes in accordance with generally accepted accounting
      principles;

   c. Evaluated the effectiveness of the registrant's disclosure controls and
      procedures and presented in this report my conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end of
      the period covered by this report based on such evaluation; and

   d. Disclosed in this report any change in the registrant's internal control
      over financial reporting that occurred during the registrant's most recent
      fiscal quarter (the registrant's fourth fiscal quarter in the case of an
      annual report) that has materially affected, or is reasonably likely to
      materially affect, the registrant's internal control over financial
      reporting; and






                                        1

5. I have disclosed, based on my most recent evaluation of internal control over
   financial reporting, to the registrant's auditors and the audit committee of
   the registrant's board of directors (or persons performing the equivalent
   functions):

   a. All significant deficiencies and material weaknesses in the design or
      operation of internal control over financial reporting which are
      reasonably likely to adversely affect the registrant's ability to record,
      process, summarize and report financial information; and

   b. Any fraud, whether or not material, that involves management or other
      employees who have a significant role in the registrant's internal control
      over financial reporting.


     /s/Chris M. Hymel

     Chris M. Hymel
     President/Treasurer


May 13, 2015




































                                        2

EX-32

Exhibit 32.1:  Certification of Chief Executive Officer and Chief Financial
               Officer under Section 1350 as Adopted Pursuant Section 906 of
               the Sarbanes-Oxley Act



               CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
                           AS ADOPTED PURSUANT TO
                SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned officer of Signal Advance, Inc. (the "Company"), hereby
certifies, to such officer's knowledge, that the Company's Quarterly Report
on Form 10-Q for the interim three month period ended March 31, 2015 (the
"Report") fully complies with the requirements of Section 13(a) of the
Securities Exchange Act of 1934 and that the information contained in the
Report fairly presents, in all material respects, the financial condition
and results of operations of the Company.



     /s/Chris M. Hymel

     Chris M. Hymel
     President/Treasurer


May 15, 2014

XML

EQUITY (Detail Textuals) (USD $)	3 Months Ended	0 Months Ended
	Mar. 31, 2015	May 13, 2015
Consultant
Stockholders' Equity Note [Line Items]
Common stock issued for services (in shares)	21,667
Value of common stock issued for services	$ 32,500
Consultant | Subsequent event
Stockholders' Equity Note [Line Items]
Common stock issued for services (in shares)		25,000
Value of common stock issued for services		25,000
Board of director
Stockholders' Equity Note [Line Items]
Common stock issued for services (in shares)	10,000
Value of common stock issued for services	$ 15,000
Number of directors	3

XML

PROPERTY AND EQUIPMENT

3 Months Ended

Mar. 31, 2015

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE D - PROPERTY AND EQUIPMENT

Property and equipment as of March 31, 2015 and December 31, 2014 are summarized as follows:

	March 31, 2015			December 31, 2014
Cost / Basis	$	128,778		$	128,475
Accumulated depreciation		(124,113	)		(123,745	)
Total property and equipment, net	$	4,665		$	4,730

Depreciation expense during the three months ended March 31, 2015 and 2014 were $368 and $415, respectively.

XML

AVAILABLE FOR SALE SECURITIES

3 Months Ended

Mar. 31, 2015

Available-for-sale Securities [Abstract]

AVAILABLE FOR SALE SECURITIES

NOTE C - AVAILABLE FOR SALE SECURITIES

Approximate cost and fair value of available for sale securities (acquired January 10, 2011) as of March 31, 2015 and December 31, 2014 are as follows:

		Cost Gross		Gain(Loss)			Fair Value
Equity Securities Available for Sale	March 31, 2015	$	25,000	$	(25,000	)		-
Equity Securities Available for Sale	December 31, 2014	$	25,000	$	(25,000	)		-

XML

Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current Assets
Cash or Cash Equivalent	$ 4,125	$ 37,177
Total Current Assets	4,125	37,177
Property and Equipment, net	4,665	4,730
Total Property and Equipment, net	4,665	4,730
Other Assets
Long-Term Investments		21,438
Total Other Assets		21,438
TOTAL ASSETS	8,790	63,345
Liabilities
Line of Credit - Shareholder	25,945	10,769
Total Liabilities	25,945	10,769
Commitments
Shareholders' deficit
Common Stock - $0 par value 100,000,000 shares authorized - shares issued and outstanding 10,305,077, as of March 31, 2015 10,273,410, as of December 31, 2014
Additional paid-in capital	5,177,835	5,130,335
Accumulated other comprehensive loss	(24,930)	(24,930)
Accumulated deficit	(5,170,060)	(5,052,829)
Total shareholders' equity (deficit)	(17,155)	52,576
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY (DEFICIT)	$ 8,790	$ 63,345

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION: The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 2015, are not necessarily indicative of the results that may be expected for the year ended December 31, 2015.

The Company's 10-K for the year ended December 31, 2014 should be read in conjunction with this report.

RECLASSIFICATIONS: For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the financial statement presentation used in 2015.

NATURE OF OPERATIONS AND ORGANIZATION:  Signal Advance, Inc. (the Company) was incorporated in Texas on June 4, 1992, is an engineering product and procedure development and consulting firm focused on the development of applications for emerging technologies. The Company has significant experience in computer technology, distributed information systems, and data acquisition and analysis systems, as well as, medical education, intellectual property protection and medical-legal litigation support. The Company has focused its resources on the improvement of signal detection systems through the development and refinement of its proprietary "Signal Advance" technology which has potential application in a wide range of medical applications, as well as applications outside of biomedicine.

CASH AND CASH EQUIVALENTS: The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

INTANGIBLE ASSETS OR LONG LIVED ASSETS: The Company anticipates amortizing intangible assets over their estimated useful lives unless such lives are deemed indefinite. Amortized intangible assets are tested for impairment based on undiscounted cash flows, and, if impaired, written down to fair value based on either discounted cash flows or appraised values. Intangible assets with indefinite lives are tested annually for impairment and written down to fair value as required. No impairment of intangible assets has been identified during any of the periods presented.

USE OF ESTIMATES IN FINANCIAL STATEMENT PREPARATION: The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company's financial statements include amounts and all adjustments that, in the opinion of management and based on management's best estimates and judgments, are necessary to make the financial statement not misleading. Actual results could differ from those estimates.

AVAILABLE FOR SALE SECURITIES: The Company holds certain investments that are treated as available-for-sale securities (FASB ASC 320-10-25) and stated at their fair market values. All investments are available for current operations and are classified as other assets in the balance sheet. Unrealized holding gains and losses are included as a component of other comprehensive income (loss) until realized (FASB ASC 320-35-1). Realized gains and losses are included in 'Other Income (Loss)' in the income statement.

INVESTMENTS IN A LIMITED LIABILITY COMPANY: The Company holds a minor investment (3%) in a Limited Liability Company (LLC). The equity method of accounting for investments in general partnerships is generally appropriate for accounting by limited partners for their investments in limited partnerships. The Company's interest is so minor as a limited partner that the Company has virtually no influence over the operating and financial policies of the LLC. As such, accounting for the investment using the cost method is appropriate. Under the cost method, income recognized by the investor is limited to distributions received, except that distributions that exceed the investor's share of earnings after the date of the investment are applied to reduce the carrying value of the investment.

Adjustments are made for impairment annually based on an impairment analysis per ASC 350-20-65-1 where the Company compares whether the fair value of the investment is less than its carrying amount which would result in impairment. The Company has recognized impairment as the LLC is dormant, currently having no commercial activity and no such activity is anticipated in the foreseeable future. As such, an adjustment for impairment was made during the three month period ended March 31, 2015 for the entire carrying value $21,438.

RESEARCH AND DEVELOPMENT: Research and development costs are expensed as incurred until technological feasibility can be determined (FASB ASC 730-10-25). Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval, marketability, licensing, lease, or sale when the net present value and useful life is able to be determined. Payments made to third parties subsequent to the aforementioned events will be capitalized. Amounts capitalized for such payments will be included in other intangibles, less the net of the accumulated amortization, once their useful lives can be determined.

REVENUE RECOGNITION: The Company revenues are generated by: 1) Providing consulting services; 2) Licensing intellectual property; and 3) Providing consulting services to licensees to facilitate implementation.

Revenue is not recognized until it is realized or realizable and earned (FASB Concepts Statement No. 5, Recognition and Measurement in Financial Statements of Business Enterprises, paragraphs 83-84). In accordance with ASC 605, 'Revenue Recognition,' the company recognizes as revenue the fees charged clients as referenced below because 1) persuasive evidence of an arrangement exists, 2) the fees charged as royalties and/or for services are substantially fixed or determinable during the period in which services are provided or royalties are collected, 3) the company and its clients understand the specific nature and terms of the agreed upon transactions, and 4) collectability is reasonable assured after services have been rendered, or according to a royalty payment schedule.

Consulting Revenue - For revenues generated by providing engineering, scientific and medical/legal consulting services. Services are charged at an hourly rate and clients are charged and revenue is recognized monthly.

License Revenue - As part of the Company's business model and as a result of the company's on-going investment in research and development, the company plans to license and sell the rights to certain of its intellectual property (IP) including internally developed patents, trade secrets and technological know-how. The typical license will call for a non-refundable initiation fee, escalating minimum royalties to be paid before a given product is marketed, and continuing royalties based on gross sales once marketing has begun, confirmed by annual audits. The license will also include a set amount of time for consulting. Licensees will also be required to participate in patent maintenance and defense.

Certain transfers of IP to third parties may be licensing/royalty-based, transaction-based, or other forms of transfer. Licensing/royalty-based fees involve transfers in which the company earns the income over time, as a lump-sum payment or the amount of income is not fixed or determinable until the licensee sells future related products (i.e., variable royalty, based upon licensee's revenue). Accordingly, following delivery and or legal conveyance of rights to the aforementioned IP to the client, and following inception of the license term, revenue is recognized in a manner consistent with the nature of the transaction and the earnings process.

Combined License/Consulting Revenue - in certain circumstances the license agreement will also include consulting services to facilitate the use of the Company's IP, in which case the arrangement may include multiple deliverables. If the client is dependent on the consulting services of the Company to bring value to the license then the license and consulting services will be considered a single unit of accounting. If, however, the license has value to the client, independent of the consulting services provided by the Company, then each deliverable has value on a standalone basis. As such each delivered item or items shall be considered a separate unit of accounting (FASB ASC 605-25).

Alternatively, license terms may contain a citation of milestones of achievement by the licensee. Each milestone may be tied to an increase in the minimum royalty. For example, biomedical milestones may include completion of animal trials, submission and then approval of 510K applications or pre-market approval by the FDA. Each licensee pursuing a biomedical application will be expected to develop its own clinical data to secure such pre-market notification (510k) or approval. Under these circumstances, the deliverable, or unit of accounting, consideration may be contingent on the substantive achievement of one or more milestones. As such, revenue is recognized in its entirety in the period in which the milestone is achieved (FASB ASC 605-28).

During the three month period ended March 31, 2015 and 2014, the Company recognized no revenue.

PROPERTY AND EQUIPMENT:  Fixed Assets (land, buildings and equipment) are carried at cost less accumulated depreciation. Depreciation is based on the estimated service lives of depreciable assets and is provided using the straight line method. In the case of disposals, assets and related depreciation are removed from the accounts, and the net amounts, less proceeds from disposal, are included in income.

INCOME TAXES:  The Company takes an asset and liability approach to financial accounting and reporting for income taxes. The difference between the financial statement and tax basis of assets and liabilities is determined annually.  Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the periods in which they are expected to affect taxable income. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will assure full realization (FASB ASC 740). As of March 31, 2015, the Company recorded a valuation allowance that reduced its deferred tax assets to zero.

CONCENTRATIONS OF CREDIT RISK: Financial instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of investment securities. Investment securities are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities can occur in the near term and that each change could materially affect the amounts reported in the financial statement.

GOING CONCERN: The Company is currently conducting operations. However, it has not yet generated sufficient operating revenue to fund its development activities to date. As such, the Company has relied on funding by the Company's President and the sale of its common stock. There is a substantial doubt that the Company will generate sufficient revenues in future years to meet its operating cash requirements. Accordingly, the Company's ability to continue operations in the short-term depends on its success in obtaining equity or debt financing in an amount sufficient to support its operations. This could raise doubt as to its ability to continue as a going concern. The financial statements do not include any adjustments that might result from this uncertainty.

XML

PROPERTY AND EQUIPMENT (Detail Textuals) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 368	$ 415

XML

FACILITIES LEASE (Detail Textuals) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Leases [Abstract]
Operating leases, monthly rental payment	$ 700
Rental expense	$ 2,100	$ 2,100

XML

INTELLECTUAL PROPERTY

3 Months Ended

Mar. 31, 2015

Intellectual Property [Abstract]

INTELLECTUAL PROPERTY

NOTE B - INTELLECTUAL PROPERTY

Intellectual property protection is being pursued for the specifically identifiable intellectual property (IP) termed Signal Advance technology. The following table lists the patent applications and issued patents and their respective status:

Patent Office	Patent or Appl. No.	Status
United States	8452544	Issued May 2013
China	ZL 200880015288.2	Issued Nov. 2012
Europe	EP 08 75 4879.8	Under examination
Mexico	325278	Issued Apr. 2014
India	3465/KOLNP/2009	Not yet examined

Additional patent submissions related to specific applications, SA circuit configurations, and signal processing techniques are in preparation.

The IP derives from an assignment of the IP in the form of a patent application filed with the USPTO as well as any patents which issue as a result of U.S. and related international patent applications.

As ASSIGNEE, the Company is responsible for:

1) funding and executing activities required for any regulatory approval, development, implementation and commercialization;

2) introducing assigned products which incorporate the patent pending or patented technology to the commercial market;

3) make its best efforts to:

        a) develop and market assigned products and services, and

        b) increase and extend the commercialization of assigned products, and

4) commence the advertising and marketing assigned products not later than 24 months following the granting of the patent

The assignment was privately negotiated between the Company's President, Dr. Hymel (Assignor) and the remaining members of the board of directors for the Company (Assignee). Consideration to acquire the IP rights, in the form of equity (specifically 1,525,000 shares of SAI common stock, to date) was expensed as the assignment is considered a transaction between entities under common control (FASB ASC 805-50-30-5,6). The value of the common stock issued in exchange for the equity was based on the most recent private sales of stock (FASB ASC 505-50-30-6).  In addition, royalties are payable to Assignor on net sales and/or license fees as follows: a) <$10M: 6%; b) $10-$25M: 8%, and c)>$25M: 10%. Assignor's remedy for non-payment is the termination of the assignment.

The costs incurred in acquiring intellectual property assignments as well as the pursuit of domestic and international patent and trademark protection are expensed (included as "Intellectual Property" under expenses on the Statements of Operations. These costs include expenses to prepare and prosecute patent applications and protect the IP, include filing and issuance fees, fees for consultants, experts, advisors, patent attorneys, including foreign associates, patent applications, claims and other amendments, responses to office actions, etc. Any patent infringement case may hinder the Company's ability to generate revenues.

XML

Balance Sheets (Unaudited) (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	10,305,077	10,273,410
Common stock, shares outstanding	10,305,077	10,273,410

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) (USD $)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Percentage of minor investment in a Limited Liability Company (LLC)	3.00%
Adjustment for impairment	$ 21,438
Deferred tax assets	$ 0

XML

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	May 13, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Signal Advance Inc
Entity Central Index Key	0001545061
Trading Symbol	sigl
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		10,330,077
Document Type	10-Q
Document Period End Date	Mar. 31, 2015
Amendment Flag	false
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

XML

INTELLECTUAL PROPERTY (Details) (Intellectual property (IP))	3 Months Ended
	Mar. 31, 2015
United States
Finite-Lived Intangible Assets [Line Items]
Patent or Appl. No.	8452544
Status	Issued May 2013
China
Finite-Lived Intangible Assets [Line Items]
Patent or Appl. No.	ZL 200880015288.2
Status	Issued Nov. 2012
Europe
Finite-Lived Intangible Assets [Line Items]
Patent or Appl. No.	EP 08 75 4879.8
Status	Under examination
Mexico
Finite-Lived Intangible Assets [Line Items]
Patent or Appl. No.	325278
Status	Issued Apr. 2014
India
Finite-Lived Intangible Assets [Line Items]
Patent or Appl. No.	3465/KOLNP/2009
Status	Not yet examined

XML

Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenue
Cost of revenue
Gross Profit
Expense
General & Administrative	8,568	8,642
Depreciation	368	415
Intellectual Property	2,690	7,418
Professional Services	71,417	16,686
Impairment expense	21,438
Research & Development	12,750	10,000
Total Expense	117,231	43,161
Net loss	(117,231)	(43,161)
Components of comprehensive loss:
Unrealized loss on available for sale securities		(13)
Comprehensive loss		(13)
Comprehensive loss	$ (117,231)	$ (43,174)
Loss per share - basic and diluted (in dollars per share)	$ (0.01)	$ 0.00
Weighted average shares outstanding - basic and diluted (in shares)	10,287,132	9,662,409

XML

EQUITY

3 Months Ended

Mar. 31, 2015

Stockholders' Equity Note [Abstract]

EQUITY

NOTE G – EQUITY

During the three months ended March 31, 2015, the Company made the following Common Stock issuances:

1) 21,667 shares of common stock valued at $32,500 to consultants in exchange for services.

2) 10,000 shares of common stock valued at $15,000 to three members of the Board of Directors in exchange for services.

Subsequent to March 31, 2015, the Company issued 25,000 shares of common stock valued at $25,000 to consultants in exchange for services.

XML

FACILITIES LEASE

3 Months Ended

Mar. 31, 2015

Leases [Abstract]

FACILITIES LEASE

NOTE F - FACILITIES LEASE

The Company currently leases office space, from its president, on a month to month basis at a rate of $700 per month. Rental expense amounted to $2,100 for the three months ended March 31, 2015 and 2014.

XML

LINE OF CREDIT - SHAREHOLDER (Detail Textuals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Interest rate on line of credit, per quarter	2.50%
Remaining balance payable	$ 25,945	$ 10,769
Accrued interest	$ 633

XML

INTELLECTUAL PROPERTY (Detail Textuals)	3 Months Ended
	Mar. 31, 2015
Intellectual Property [Abstract]
Number of shares issued as consideration to acquire intellectual property rights	1,525,000
Conditions for royalty payments	Royalties are payable to Assignor on net sales and/or license fees as follows: a) <$10M: 6%; b) $10-$25M: 8%, and c)>$25M: 10%.

XML

AVAILABLE FOR SALE SECURITIES (Tables)

3 Months Ended

Mar. 31, 2015

Available-for-sale Securities [Abstract]

Schedule of cost and fair value of available for sale securities

		Cost Gross		Gain(Loss)			Fair Value
Equity Securities Available for Sale	March 31, 2015	$	25,000	$	(25,000	)		-
Equity Securities Available for Sale	December 31, 2014	$	25,000	$	(25,000	)		-

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

BASIS OF PRESENTATION

BASIS OF PRESENTATION: The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 2015, are not necessarily indicative of the results that may be expected for the year ended December 31, 2015.

The Company's 10-K for the year ended December 31, 2014 should be read in conjunction with this report.

RECLASSIFICATIONS

RECLASSIFICATIONS: For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the financial statement presentation used in 2015.

NATURE OF OPERATIONS AND ORGANIZATION

NATURE OF OPERATIONS AND ORGANIZATION:  Signal Advance, Inc. (the Company) was incorporated in Texas on June 4, 1992, is an engineering product and procedure development and consulting firm focused on the development of applications for emerging technologies. The Company has significant experience in computer technology, distributed information systems, and data acquisition and analysis systems, as well as, medical education, intellectual property protection and medical-legal litigation support. The Company has focused its resources on the improvement of signal detection systems through the development and refinement of its proprietary "Signal Advance" technology which has potential application in a wide range of medical applications, as well as applications outside of biomedicine.

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS: The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

INTANGIBLE ASSETS OR LONG LIVED ASSETS

INTANGIBLE ASSETS OR LONG LIVED ASSETS: The Company anticipates amortizing intangible assets over their estimated useful lives unless such lives are deemed indefinite. Amortized intangible assets are tested for impairment based on undiscounted cash flows, and, if impaired, written down to fair value based on either discounted cash flows or appraised values. Intangible assets with indefinite lives are tested annually for impairment and written down to fair value as required. No impairment of intangible assets has been identified during any of the periods presented.

USE OF ESTIMATES IN FINANCIAL STATEMENT PREPARATION

USE OF ESTIMATES IN FINANCIAL STATEMENT PREPARATION: The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company's financial statements include amounts and all adjustments that, in the opinion of management and based on management's best estimates and judgments, are necessary to make the financial statement not misleading. Actual results could differ from those estimates.

AVAILABLE FOR SALE SECURITIES

AVAILABLE FOR SALE SECURITIES: The Company holds certain investments that are treated as available-for-sale securities (FASB ASC 320-10-25) and stated at their fair market values. All investments are available for current operations and are classified as other assets in the balance sheet. Unrealized holding gains and losses are included as a component of other comprehensive income (loss) until realized (FASB ASC 320-35-1). Realized gains and losses are included in 'Other Income (Loss)' in the income statement.

INVESTMENTS IN A LIMITED LIABILITY COMPANY

INVESTMENTS IN A LIMITED LIABILITY COMPANY: The Company holds a minor investment (3%) in a Limited Liability Company (LLC). The equity method of accounting for investments in general partnerships is generally appropriate for accounting by limited partners for their investments in limited partnerships. The Company's interest is so minor as a limited partner that the Company has virtually no influence over the operating and financial policies of the LLC. As such, accounting for the investment using the cost method is appropriate. Under the cost method, income recognized by the investor is limited to distributions received, except that distributions that exceed the investor's share of earnings after the date of the investment are applied to reduce the carrying value of the investment.

Adjustments are made for impairment annually based on an impairment analysis per ASC 350-20-65-1 where the Company compares whether the fair value of the investment is less than its carrying amount which would result in impairment. The Company has recognized impairment as the LLC is dormant, currently having no commercial activity and no such activity is anticipated in the foreseeable future. As such, an adjustment for impairment was made during the three month period ended March 31, 2015 for the entire carrying value $21,438.

RESEARCH AND DEVELOPMENT

RESEARCH AND DEVELOPMENT: Research and development costs are expensed as incurred until technological feasibility can be determined (FASB ASC 730-10-25). Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval, marketability, licensing, lease, or sale when the net present value and useful life is able to be determined. Payments made to third parties subsequent to the aforementioned events will be capitalized. Amounts capitalized for such payments will be included in other intangibles, less the net of the accumulated amortization, once their useful lives can be determined.

REVENUE RECOGNITION

REVENUE RECOGNITION: The Company revenues are generated by: 1) Providing consulting services; 2) Licensing intellectual property; and 3) Providing consulting services to licensees to facilitate implementation.

Revenue is not recognized until it is realized or realizable and earned (FASB Concepts Statement No. 5, Recognition and Measurement in Financial Statements of Business Enterprises, paragraphs 83-84). In accordance with ASC 605, 'Revenue Recognition,' the company recognizes as revenue the fees charged clients as referenced below because 1) persuasive evidence of an arrangement exists, 2) the fees charged as royalties and/or for services are substantially fixed or determinable during the period in which services are provided or royalties are collected, 3) the company and its clients understand the specific nature and terms of the agreed upon transactions, and 4) collectability is reasonable assured after services have been rendered, or according to a royalty payment schedule.

Consulting Revenue - For revenues generated by providing engineering, scientific and medical/legal consulting services. Services are charged at an hourly rate and clients are charged and revenue is recognized monthly.

License Revenue - As part of the Company's business model and as a result of the company's on-going investment in research and development, the company plans to license and sell the rights to certain of its intellectual property (IP) including internally developed patents, trade secrets and technological know-how. The typical license will call for a non-refundable initiation fee, escalating minimum royalties to be paid before a given product is marketed, and continuing royalties based on gross sales once marketing has begun, confirmed by annual audits. The license will also include a set amount of time for consulting. Licensees will also be required to participate in patent maintenance and defense.

Certain transfers of IP to third parties may be licensing/royalty-based, transaction-based, or other forms of transfer. Licensing/royalty-based fees involve transfers in which the company earns the income over time, as a lump-sum payment or the amount of income is not fixed or determinable until the licensee sells future related products (i.e., variable royalty, based upon licensee's revenue). Accordingly, following delivery and or legal conveyance of rights to the aforementioned IP to the client, and following inception of the license term, revenue is recognized in a manner consistent with the nature of the transaction and the earnings process.

Combined License/Consulting Revenue - in certain circumstances the license agreement will also include consulting services to facilitate the use of the Company's IP, in which case the arrangement may include multiple deliverables. If the client is dependent on the consulting services of the Company to bring value to the license then the license and consulting services will be considered a single unit of accounting. If, however, the license has value to the client, independent of the consulting services provided by the Company, then each deliverable has value on a standalone basis. As such each delivered item or items shall be considered a separate unit of accounting (FASB ASC 605-25).

Alternatively, license terms may contain a citation of milestones of achievement by the licensee. Each milestone may be tied to an increase in the minimum royalty. For example, biomedical milestones may include completion of animal trials, submission and then approval of 510K applications or pre-market approval by the FDA. Each licensee pursuing a biomedical application will be expected to develop its own clinical data to secure such pre-market notification (510k) or approval. Under these circumstances, the deliverable, or unit of accounting, consideration may be contingent on the substantive achievement of one or more milestones. As such, revenue is recognized in its entirety in the period in which the milestone is achieved (FASB ASC 605-28).

During the three month period ended March 31, 2015 and 2014, the Company recognized no revenue.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT:  Fixed Assets (land, buildings and equipment) are carried at cost less accumulated depreciation. Depreciation is based on the estimated service lives of depreciable assets and is provided using the straight line method. In the case of disposals, assets and related depreciation are removed from the accounts, and the net amounts, less proceeds from disposal, are included in income.

INCOME TAXES

INCOME TAXES:  The Company takes an asset and liability approach to financial accounting and reporting for income taxes. The difference between the financial statement and tax basis of assets and liabilities is determined annually.  Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the periods in which they are expected to affect taxable income. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will assure full realization (FASB ASC 740). As of March 31, 2015, the Company recorded a valuation allowance that reduced its deferred tax assets to zero.

CONCENTRATIONS OF CREDIT RISK

CONCENTRATIONS OF CREDIT RISK: Financial instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of investment securities. Investment securities are exposed to various risks, such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities can occur in the near term and that each change could materially affect the amounts reported in the financial statement.

GOING CONCERN

GOING CONCERN: The Company is currently conducting operations. However, it has not yet generated sufficient operating revenue to fund its development activities to date. As such, the Company has relied on funding by the Company's President and the sale of its common stock. There is a substantial doubt that the Company will generate sufficient revenues in future years to meet its operating cash requirements. Accordingly, the Company's ability to continue operations in the short-term depends on its success in obtaining equity or debt financing in an amount sufficient to support its operations. This could raise doubt as to its ability to continue as a going concern. The financial statements do not include any adjustments that might result from this uncertainty.

XML

INTELLECTUAL PROPERTY (Tables)

3 Months Ended

Mar. 31, 2015

Intellectual Property [Abstract]

Schedule of patent applications and issued patents

Patent Office	Patent or Appl. No.	Status
United States	8452544	Issued May 2013
China	ZL 200880015288.2	Issued Nov. 2012
Europe	EP 08 75 4879.8	Under examination
Mexico	325278	Issued Apr. 2014
India	3465/KOLNP/2009	Not yet examined

XML

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2015

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	March 31, 2015			December 31, 2014
Cost / Basis	$	128,778		$	128,475
Accumulated depreciation		(124,113	)		(123,745	)
Total property and equipment, net	$	4,665		$	4,730

XML

PROPERTY AND EQUIPMENT (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Cost / Basis	$ 128,778	$ 128,475
Accumulated depreciation	(124,113)	(123,745)
Total property and equipment, net	$ 4,665	$ 4,730

XML

Statements of Cash Flow (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
OPERATING ACTIVITIES
Net loss	$ (117,231)	$ (43,161)
Adjustments to reconcile Net Income to net cash provided by operations:
Depreciation	368	415
Impairment of investment	21,438
Stock Compensation	47,500	100,000
Net cash provided by (used in) Operating Activities	(47,925)	57,254
INVESTING ACTIVITIES
Purchase of property and equipment	(303)	(660)
Net cash used in Investing Activities	(303)	(660)
FINANCING ACTIVITIES
Capital Investment: Cash		42,000
Line of Credit - Shareholder, net	15,176	(81,599)
Net cash provided by (used in) Financing Activities	15,176	(39,599)
Net cash increase (decrease) for period	(33,052)	16,995
Cash at beginning of period	37,177	11,497
Cash at end of period	4,125	28,492
Supplemental Disclosure
Interest paid	633	898
Non-Cash Transactions:
Unrealized loss on available for sale securities		13
Repayment of line of credit - shareholder in common stock		$ 100,000

XML

LINE OF CREDIT - SHAREHOLDER

3 Months Ended

Mar. 31, 2015

Debt Disclosure [Abstract]

LINE OF CREDIT - SHAREHOLDER

Note E – LINE OF CREDIT - SHAREHOLDER

The President has loaned funds to the Company under the terms of a Line of Credit Promissory Note negotiated with, and approved by, the Board of Directors. The line of credit is due on demand, unsecured, and bears interest at 2.5% per quarter.

As of March 31, 2015, the remaining balance payable was $25,945 including accrued interest of $633.

XML

AVAILABLE FOR SALE SECURITIES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Available-for-sale Securities [Abstract]
Equity Securities Available for Sale, Cost Gross	$ 25,000	$ 25,000
Equity Securities Available for Sale, Gain (Loss)	(25,000)	(25,000)
Equity Securities Available for Sale, Fair Value